

ANTI-VIRAL ANTIBODY PRODUCTION OF DUAL-SUBTYPE VACCINATED CATS DETECTED BY IMMUNOBLOT

Pet	3G2	0 2 4	
${ m FIV}_{ m Pet}$	3G1	0 2 4 0 2 4	
	666	0 2 4 0 2 4 0 2 4 0 2 4	
/shi	200	0 2 4	
FIV_{Shi}	900	0 2 4	
	M55	0 2 4	
	973	0 2 4	
t + Shi	31.4	0 2 4 0 2 4 0 2 4 0 2 4	
FIV _{Pet} + Shi	NSS	0 2 4	
	K55	0 2 4	
VACCINE	CAT#	SERUM COLLECTION (post-vaccinations*)	p25 →

Before challenge.

FIG. 2

ANTI-VIRAL ANTIBODY PRODUCTION OF TRIPLE-SUBTYPE VACCINATED CATS

CAIS					
NATED		RD2	0 2 3		
E VACCI	$\mathrm{FIV}_{\mathtt{Bang}}$	OU8	023 023 023		
SUBIYP BLOT		BEA	0 2 3		
F TRIPLE IMMUNO	Вu	TAS	0 2 3		
PRODUCTION OF TRIPLE-SUBT	FIV _{Pet + Shi + Bang}	QY1	023 023 023		
	FI	J55	0 2 3	·	
I-VIKAL ANTIBODY PRODUCTION OF TRIPLE-SUBTYPE VACCINATED CATS DETECTED BY IMMUNOBLOT	VACCINE	CAT #	SERUM COLLECTION	(post-vaccinations*)	p25 →

Before challenge.

FIG. 3

Fig. 4A








Fig. 5A











NA TITER